

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 61561

Title: Lenvatinib-induced multiorgan adverse events in Hurthle cell thyroid cancer: A case report

Reviewer's code: 03434660

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: Saudi Arabia

Manuscript submission date: 2020-12-22

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-12-24 01:19

Reviewer performed review: 2021-01-03 02:51

Review time: 10 Days and 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

SPECIFIC COMMENTS TO AUTHORS

Muhammad IB et al. report a case with Hurthle cell thyroid cancer who experienced severe adverse effects including cardiomyopathy, bi-cytopenia, renal impairment, and rarely reported nephrotic syndrome underwent Lenvatinib treatment. This case serves a reminder of the adverse drug reactions associated with the use of TKIs. The theme is distinct and content is clear, and will be useful as a guide to clinical therapy. However, the authors has not fully described scientific rationale for choosing Lenvatinib.

RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 61561

Title: Lenvatinib-induced multiorgan adverse events in Hurthle cell thyroid cancer: A case report

Reviewer's code: 03434660

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: Saudi Arabia

Manuscript submission date: 2020-12-22

Reviewer chosen by: Chen-Chen Gao

Reviewer accepted review: 2021-02-02 09:13

Reviewer performed review: 2021-02-02 09:38

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

This case serves a reminder of the adverse drug reactions associated with the use of TKIs. The theme is distinct and content is clear, and will be useful as a guide to clinical therapy.